Coherus BioSciences (CHRS) Receives Adverse PTAB Decision Over HUMIRA IPR
Tweet Send to a Friend
Coherus BioSciences, Inc. (Nasdaq: CHRS) announced that it has received a decision from the Patent Trial and Appeal Board (PTAB) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
